Related references
Note: Only part of the references are listed.Wnt5a enhances proliferation of chronic lymphocytic leukemia and ERK1/2 phosphorylation via a ROR1/DOCK2-dependent mechanism
Md Kamrul Hasan et al.
LEUKEMIA (2021)
Regulation of Bcl-XL by non-canonical NF-κB in the context of CD40-induced drug resistance in CLL
Marco Haselager et al.
CELL DEATH AND DIFFERENTIATION (2021)
Tyrosine Kinase ROR1 as a Target for Anti-Cancer Therapies
Yuming Zhao et al.
FRONTIERS IN ONCOLOGY (2021)
NF-κB-p62-NRF2 survival signaling is associated with high ROR1 expression in chronic lymphocytic leukemia
Elsa Sanchez-Lopez et al.
CELL DEATH AND DIFFERENTIATION (2020)
Novel Targeted Therapies for Chronic Lymphocytic Leukemia in Elderly Patients: A Systematic Review
Arafat Ali Farooqui et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2020)
Ibrutinib dose modifications in the management of CLL
Camille Hardy-Abeloos et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)
Activation of hedgehog signaling associates with early disease progression in chronic lymphocytic leukemia
Emanuela M. Ghia et al.
BLOOD (2019)
Cirmtuzumab blocks Wnt5a/ROR1 stimulation of NF-κB to repress autocrine STAT3 activation in chronic lymphocytic leukemia
Yun Chen et al.
BLOOD (2019)
STAT3-Induced Wnt5a Provides Chronic Lymphocytic Leukemia Cells with Survival Advantage
Uri Rozovski et al.
JOURNAL OF IMMUNOLOGY (2019)
Wnt5a causes ROR1 to complex and activate cortactin to enhance migration of chronic lymphocytic leukemia cells
Md Kamrul Hasan et al.
LEUKEMIA (2019)
Frontline therapies for untreated chronic lymphoid leukemia
Delong Liu et al.
EXPERIMENTAL HEMATOLOGY & ONCOLOGY (2019)
Targeted Therapy in Chronic Lymphocytic Leukemia
Thomas J. Kipps et al.
CANCER JOURNAL (2019)
Wnt5a induces ROR1 to recruit DOCK2 to activate Rac1/2 in chronic lymphocytic leukemia
Md Kamrul Hasan et al.
BLOOD (2018)
Phase I Trial: Cirmtuzumab Inhibits ROR1 Signaling and Stemness Signatures in Patients with Chronic Lymphocytic Leukemia
Michael Y. Choi et al.
CELL STEM CELL (2018)
Venetoclax: A new wave in hematooncology
Jana Mihalyova et al.
EXPERIMENTAL HEMATOLOGY (2018)
Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in he United States
Anthony R. Mato et al.
HAEMATOLOGICA (2018)
Autologous T-cell activation fosters ABT-199 resistance in chronic lymphocytic leukemia: rationale for a combined therapy with SYK inhibitors and anti-CD20 monoclonal antibodies
Esteban Enrique Elias et al.
HAEMATOLOGICA (2018)
BCL-2 as therapeutic target for hematological malignancies
Guilherme Fleury Perini et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)
Critical molecular pathways in CLL therapy
Gerardo Ferrer et al.
MOLECULAR MEDICINE (2018)
Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in he United States
Anthony R. Mato et al.
HAEMATOLOGICA (2018)
Autologous T-cell activation fosters ABT-199 resistance in chronic lymphocytic leukemia: rationale for a combined therapy with SYK inhibitors and anti-CD20 monoclonal antibodies
Esteban Enrique Elias et al.
HAEMATOLOGICA (2018)
Wnt5a induces ROR1 to associate with 14-3-3ζ for enhanced chemotaxis and proliferation of chronic lymphocytic leukemia cells
J. Yu et al.
LEUKEMIA (2017)
Wnt5a induces ROR1 to complex with HS1 to enhance migration of chronic lymphocytic leukemia cells
M. K. Hasan et al.
LEUKEMIA (2017)
Chronic lymphocytic leukaemia
Thomas J. Kipps et al.
NATURE REVIEWS DISEASE PRIMERS (2017)
Microenvironmental agonists generate de novo phenotypic resistance to combined ibrutinib plus venetoclax in CLL and MCL
Kallesh D. Jayappa et al.
BLOOD ADVANCES (2017)
Autocrine Signaling by Wnt-5a Deregulates Chemotaxis of Leukemic Cells and Predicts Clinical Outcome in Chronic Lymphocytic Leukemia
Pavlina Janovska et al.
CLINICAL CANCER RESEARCH (2016)
Wnt5a induces ROR1/ROR2 heterooligomerization to enhance leukemia chemotaxis and proliferation
Jian Yu et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
Identification of an orally available compound with potent and broad FLT3 inhibition activity
Y. Chen et al.
ONCOGENE (2016)
BCR signaling inhibitors differ in their ability to overcome Mcl-1-mediated resistance of CLL B cells to ABT-199
Kamil Bojarczuk et al.
BLOOD (2016)
High-level ROR1 associates with accelerated disease progression in chronic lymphocytic leukemia
Bing Cui et al.
BLOOD (2016)
Cancer Statistics, 2016
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2016)
Mist1 Expressing Gastric Stem Cells Maintain the Normal and Neoplastic Gastric Epithelium and Are Supported by a Perivascular Stem Cell Niche
Yoku Hayakawa et al.
CANCER CELL (2015)
Wnt5a promotes human colon cancer cell migration and invasion but does not augment intestinal tumorigenesis in Apc1638N mice
Elvira R. M. Bakker et al.
CARCINOGENESIS (2013)
SU11652 Inhibits tyrosine kinase activity of FLT3 and growth of MV-4-11 cells
Yao Guo et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2012)
A novel role of the CX3CR1/CX3CL1 system in the cross-talk between chronic lymphocytic leukemia cells and tumor microenvironment
E. Ferretti et al.
LEUKEMIA (2011)
Antisera induced by infusions of autologous Ad-CD154-leukemia B cells identify ROR1 as an oncofetal,antigen and receptor for Wnt5a
Tetsuya Fukuda et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Nurselike cells express BAFF and APRIL, which can promote survival of chronic lymphocytic leukemia cells via a paracrine pathway distinct from that of SDF-1α
M Nishio et al.
BLOOD (2005)
Distinctive features of nurselike cells that differentiate in the context of chronic lymphocytic leukemia
N Tsukada et al.
BLOOD (2002)
Share Paper
